论文部分内容阅读
目的探讨血清人附睾上皮分泌蛋白4(HE4)、糖类抗原125(CA125)联合卵巢恶性肿瘤风险模型(ROMA)值在卵巢癌及盆腔良性疾病中的诊断价值。方法选取河北省冀中能源峰峰集团总医院2015年2月—2016年2月收治的卵巢癌及盆腔良性疾病患者173例,根据不同疾病将所有患者分为卵巢癌组49例和盆腔良性疾病组124例,另随机选取同期健康体检女性41例为健康对照组。测定比较3组受试者血清HE4和CA125及ROMA值,计算HE4、CA125及ROMA值诊断卵巢癌及盆腔良性疾病的灵敏度、特异度及诊断符合率。结果 3组受试者血清HE4、CA125及ROMA值比较,差异有统计学意义(P<0.05)。其中,卵巢癌组患者血清HE4、CA125和ROMA值高于健康对照组(P<0.05);盆腔良性疾病组患者血清CA125、ROMA值高于健康对照组(P<0.05);卵巢癌组患者ROMA值高于盆腔良性疾病组(P<0.05)。血清HE4诊断疾病的灵敏度为79.59%(39/49),特异度为93.55%(116/124),诊断符合率为89.59%(155/173);CA125诊断疾病的灵敏度为75.51%(37/49),特异度为79.03%(98/124),诊断符合率为78.03%(135/173);ROMA值诊断疾病的灵敏度为87.75%(43/49),特异度为80.64%(100/124),诊断符合率为82.66%(143/173)。结论血清HE4、CA125检测联合ROMA值可提高卵巢癌及盆腔良性疾病的诊断准确率,具有较大的临床预测价值。
Objective To investigate the diagnostic value of serum human epididymal epithelial secrection protein 4 (HE4), carbohydrate antigen 125 (CA125) combined with ovarian malignant tumor risk model (ROMA) in ovarian cancer and pelvic benign disease. Methods 173 cases of ovarian cancer and pelvic benign disease were selected from Hebei Fengzhong Fengfeng Group General Hospital from February 2015 to February 2016. According to different diseases, all patients were divided into ovarian cancer group (49 cases) and pelvic benign disease The other 124 patients were randomly selected from 41 healthy women during the same period as the healthy control group. The serum levels of HE4, CA125 and ROMA in three groups of subjects were measured and compared. The sensitivity, specificity and diagnostic accuracy of HE4, CA125 and ROMA in diagnosing ovarian cancer and pelvic benign disease were calculated. Results The serum HE4, CA125 and ROMA values of the three groups were significantly different (P <0.05). Among them, the serum levels of HE4, CA125 and ROMA in patients with ovarian cancer were significantly higher than those in healthy controls (P <0.05). The serum CA125 and ROMA values in patients with benign disease of the pelvis were significantly higher than those in healthy controls (P <0.05) Value higher than pelvic benign disease group (P <0.05). The diagnostic sensitivity of HE4 was 79.59% (39/49), the specificity was 93.55% (116/124), and the diagnostic coincidence rate was 89.59% (155/173). The sensitivity of diagnosing CA125 was 75.51% (37/49) ), The specificity was 79.03% (98/124), the diagnostic coincidence rate was 78.03% (135/173). The diagnostic sensitivity of ROMA was 87.75% (43/49) and the specificity was 80.64% (100/124) , The diagnostic coincidence rate was 82.66% (143/173). Conclusion Serum HE4, CA125 combined with ROMA value can improve the diagnostic accuracy of ovarian cancer and pelvic benign disease, with great clinical predictive value.